WallStSmart

Elevance Health Inc (ELV)vsKLA Corporation (KLAC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Elevance Health Inc generates 1430% more annual revenue ($200.42B vs $13.10B). KLAC leads profitability with a 35.7% profit margin vs 2.6%. ELV appears more attractively valued with a PEG of 1.43. KLAC earns a higher WallStSmart Score of 68/100 (B-).

ELV

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 5.5Value: 8.0Quality: 5.0
Piotroski: 3/9

KLAC

Strong Buy

68

out of 100

Grade: B-

Growth: 6.0Profit: 10.0Value: 4.3Quality: 7.0
Piotroski: 6/9Altman Z: 2.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ELVUndervalued (+63.5%)

Margin of Safety

+63.5%

Fair Value

$1011.48

Current Price

$374.71

$636.77 discount

UndervaluedFair: $1011.48Overvalued

Intrinsic value data unavailable for KLAC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELV4 strengths · Avg: 8.3/10
Market CapQuality
$80.93B9/10

Large-cap with strong market position

P/E RatioValuation
15.8x8/10

Attractively priced relative to earnings

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$4.10B8/10

Generating 4.1B in free cash flow

KLAC4 strengths · Avg: 10.0/10
Market CapQuality
$226.82B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
95.0%10/10

Every $100 of equity generates 95 in profit

Profit MarginProfitability
35.7%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
41.2%10/10

Strong operational efficiency at 41.2%

Areas to Watch

ELV4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Profit MarginProfitability
2.6%3/10

2.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-16.8%2/10

Earnings declined 16.8%

KLAC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

Debt/EquityHealth
1.153/10

Elevated debt levels

P/E RatioValuation
48.8x2/10

Premium valuation, high expectations priced in

Price/BookValuation
43.6x2/10

Trading at 43.6x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ELV

The strongest argument for ELV centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bull Case : KLAC

The strongest argument for KLAC centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.7% and operating margin at 41.2%. Revenue growth of 11.5% demonstrates continued momentum.

Bear Case : ELV

The primary concerns for ELV are Revenue Growth, Profit Margin, Piotroski F-Score. Thin 2.6% margins leave little buffer for downturns.

Bear Case : KLAC

The primary concerns for KLAC are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 48.8x leaves little room for execution misses.

Key Dynamics to Monitor

ELV profiles as a value stock while KLAC is a mature play — different risk/reward profiles.

KLAC carries more volatility with a beta of 1.44 — expect wider price swings.

KLAC is growing revenue faster at 11.5% — sustainability is the question.

ELV generates stronger free cash flow (4.1B), providing more financial flexibility.

Bottom Line

KLAC scores higher overall (68/100 vs 56/100), backed by strong 35.7% margins and 11.5% revenue growth. ELV offers better value entry with a 63.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elevance Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.

KLA Corporation

TECHNOLOGY · SEMICONDUCTOR EQUIPMENT & MATERIALS · USA

KLA Corporation is a capital equipment company based in Milpitas, California. It supplies process control and yield management systems for the semiconductor industry and other related nanoelectronics industries. The company's products and services are intended for all phases of wafer, reticle, integrated circuit (IC) and packaging production, from research and development to final volume manufacturing.

Visit Website →

Want to dig deeper into these stocks?